LONDON, May 1 (Reuters) - Shire (LSE: SHP.L - news) , a pharmaceuticalgroup created by acquisition, soundly beat expectations with a38 percent rise in first-quarter earnings, underlining its ownappeal as a target in the latest wave of deal making in thesector.
Shire, which has franchises in drugs to treat hyperactivityand rare diseases, reported earnings per share-ADS of $2.36, itspreferred measure, on revenue of $1.35 billion, boosted bystrong sales across its portfolio.
The group raised its outlook for earnings growth this yearto mid-to-high 20 percent growth from its previous prediction ofsimilar growth to the 23 percent it recorded in 2013.
Shire, which has a market capitalization of $33 billion, haslong outpaced its big pharma rivals growing revenues andprofits. Its base in Dublin, which has a lower rate ofcorporation tax than many countries including the United States,adds to its appeal.
Analysts expected Shire to post revenue of $1.38 billion andnon-GAAP earnings per ADS of $2.22, according to a companycompiled poll of 19 brokers.
(Reporting by Paul Sandle; editing by Kate Holton)
- Investment & Company Information